Madrigal Pharmaceuticals, Inc. (MDGL) SEC Filings & Earnings Calls

Operating expenses growing faster than revenue; path to profitability uncertain.

“Operating expenses $420.6M vs $260.0M; cost of sales increased significantly.”

Dependence on single product Rezdiffra for revenue.

“All revenue from Rezdiffra; pipeline still early stage.”

Inventory write-down risk

“a write-down of $10.4 million for certain work-in-process inventory that may not meet quality specifications.” · word for word

Dependence on single product Rezdiffra

“We began generating revenue from sales of Rezdiffra in the United States in April 2024.” · word for word

High cash burn rate

“Net cash used in operating activities was $144.1 million for the six months ended June 30, 2026” · word for word

Commercial execution risk

“We expect cost of sales to increase in the future, as manufacturing costs incurred prior to regulatory approval were expensed to research and development rather than capitalized as inventory.” · word for word

Pipeline dependency risk

“The probability of success for each product candidate is affected by numerous factors, including preclinical data, clinical data, competition, manufacturing capability and commercial viability.” · word for word

High operating expense growth (86.6% YoY) driven by commercial investment and upfront BD costs; profitability may be pressured if revenue growth decelerates.

“Operating expenses $404.1M vs $216.6M prior year; includes $54.3M upfront BD expenses.”

Dependence on Rezdiffra for revenue; pipeline assets are early-stage and may not materialize.

“Revenue entirely from Rezdiffra; siRNA assets are clinical/pre-clinical.”

Single product dependency

“We are highly dependent on the success of our only approved product, Rezdiffra.” · word for word

Accelerated/conditional approval requires confirmatory data

“We obtained accelerated approval in the United States and conditional marketing authorization in the European Union for Rezdiffra, and we are subject to certain post-marketing commitments.” · word for word

Operating losses and need for additional capital

“We have a history of operating losses, expect to incur operating losses in the future and may never achieve or maintain profitability.” · word for word

Operating expenses growing faster than revenue; R&D and SG&A costs high.

“Operating expenses $380.7M in Q4 2025 vs $170.3M prior year; R&D expense increased significantly.”

Dependence on Roche partnership; royalty terms modified but still material.

“royalty payable to Roche based on net sales of Rezdiffra will not be reduced until the expiration of certain patent term extensions” · word for word

No material risk; routine executive appointment.

“appointment of new CAO, no departure of key officers”

Dependence on Rezdiffra for revenue; pipeline risk with oral GLP-1 still in preclinical stage.

“MGL-2086 is expected to enter the clinic in the first half of 2026.”

High operating expenses due to commercialization and R&D; potential for future dilution.

“Operating Expenses: Third-quarter 2025 operating expenses were $401.2 million, compared to $178.5 million in the comparable prior year period.” · word for word

Commercial Execution Risk

“We expect that our selling, general and administrative expenses will increase in the future as we expand our operating activities, continue commercialization efforts.” · word for word

Pipeline Dependency

“We plan to selectively in-license or acquire rights to programs at all stages of development to take advantage of our drug development and commercial capabilities.” · word for word

Debt Covenant Risk

“We and the Guarantors are also required to maintain a minimum unrestricted cash balance of $100.0 million at all times.”